Description
Opinion Only. Not for Medical Reference. Written by Nevin Pratt
DSIP
A 9-amino acide peptide named by Swiss researchers in the 1970’s as “Delta Sleep Inducing Peptide”.
The FDA is meeting with the Pharmacy Compounding Advisory Committee (PCAC) on 7/24/26 to evaluate DSIP forfor opioid withdrawal, chronic insomnia, and narcolepsy.
DSIP-like material has been found in human brain, plasma, pituitary tissue, and even breast milk, which strongly suggests it’s part of our endogenous physiology. It touches the hypothalamus and pituitary, tweaks stress hormones like ACTH and cortisol, nudges luteinizing hormone and growth hormone, and influences neurotransmitters tied to stress, mood, and pain. Because of all that it does, current researchers seem to refer to it less as a sleep inducer and more as a circadiam rhythm peptide that just happens to help with sleep.
In a chronic pain pilot study, 6 out of 7 patients with things like migraines, psychosomatic pain, and tinnitus-associated pain had significant pain reduction after DSIP therapy. Many of these cases were long-standing and hard to treat. Their depressive symptoms improved alongside the pain.
In small insomnia trials (including a multi-study series by Schneider-Helmert and colleagues), insomniacs given DSIP for a few nights saw complete normalization of sleep patterns. Sleep architecture returned to the range seen in people without insomnia after just four nights of treatment. No next-day hangover and actually better daytime alertness and cognitive performance than placebo.
In cancer research, miceinjected monthly with DSIP had a 2.6-fold drop in spontaneous tumors and lived 24% longer. https://pubmed.ncbi.nlm.nih.
Dosage: 100-500mcg daily, cycled. 10 days on, 5 days off.
For defense against Alzheimer’s, stack it with Epitalon and MOTS-C
5mg vial 2cc BAC, 20 units = 500mcg
